Generalised anxiety disorder therapeutic - SIMR Biotech
Alternative Names: General anxiety disorder therapeutic - SMIR BiotechLatest Information Update: 04 Jul 2025
At a glance
- Originator SIMR Biotech
- Class Anxiolytics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Generalised anxiety disorder
Most Recent Events
- 03 Jul 2025 Generalised anxiety disorder therapeutic - SIMR Biotech is available for licensing as of 23 Jun 2025. http://www.simrbio.com/en/PARTNER/
- 23 Jun 2025 Preclinical trials in Generalised anxiety disorder in China (unspecified route) before June 2025 (SIMR Biotech pipeline, June 2025)